Silence Therapeutics priced an upsized public offering expected to raise about $175 million to support its short interfering RNA pipeline, including divesiran after a “best-case” outcome in a Phase 2 study for a rare leukemia. The financing expands on a previously announced plan and signals continued investor appetite for late-stage-leaning RNA platforms. The offering’s scale matters for operational runway as sponsors balance clinical follow-ons, manufacturing readiness, and regulatory planning. For the market, it also reinforces how companies are funding highly specific RNA therapeutics after early clinical signals.